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ORIGINAL ARTICLE
Endoglin targeting inhibits tumor angiogenesis and metastatic
spread in breast cancer
M Paauwe1,2, RC Heijkants1, CH Oudt1, GW van Pelt3, C Cui1, CP Theuer4, JCH Hardwick2, CFM Sier2,3 and LJAC Hawinkels1,2
Endoglin, a transforming growth factor-β co-receptor, is highly expressed on angiogenic endothelial cells in solid tumors. Therefore,
targeting endoglin is currently being explored in clinical trials for anti-angiogenic therapy. In this project, the redundancy between
endoglin and vascular endothelial growth factor (VEGF) signaling in angiogenesis and the effects of targeting both pathways on
breast cancer metastasis were explored. In patient samples, increased endoglin signaling after VEGF inhibition was observed.
In vitro TRC105, an endoglin-neutralizing antibody, increased VEGF signaling in endothelial cells. Moreover, combined targeting
of the endoglin and VEGF pathway, with the VEGF receptor kinase inhibitor SU5416, increased antiangiogenic effects in vitro and in
a zebrafish angiogenesis model. Next, in a mouse model for invasive lobular breast cancer, the effects of TRC105 and SU5416 on
tumor growth and metastasis were explored. Although TRC105 and SU5416 decreased tumor vascular density, tumor volume was
unaffected. Strikingly, in mice treated with TRC105, or TRC105 and SU5416 combined, a strong inhibition in the number of
metastases was seen. Moreover, upon resection of the primary tumor, strong inhibition of metastatic spread by TRC105 was
observed in an adjuvant setting. To confirm these data, we assessed the effects of endoglin-Fc (an endoglin ligand trap) on
metastasis formation. Similar to treatment with TRC105 in the resection model, endoglin-Fc-expressing tumors showed strong
inhibition of distant metastases. These results show, for the first time, that targeting endoglin, either with neutralizing antibodies or
a ligand trap, strongly inhibits metastatic spread of breast cancer in vivo.
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INTRODUCTION
Breast cancer is the second most common form of cancer globally,
with over 1.5 million diagnosed patients in 2012.1 Primary
treatment for breast cancer patients is surgical removal of the
tumor, complemented with adjuvant therapies like (chemo-)
radiation or antiangiogenic therapies. The formation of a vascular
network, called angiogenesis, is crucial for solid tumors to sustain
oxygen and nutrient supply, but also indispensable for their
metastatic spread.2,3 Therefore, antiangiogenic therapies have
been developed for the treatment of solid cancers. Vascular
endothelial growth factor (VEGF) is one of the major players in the
induction of angiogenesis and therefore many antiangiogenic
agents have been developed against VEGF.4 Although preclinical
data of the first VEGF-neutralizing antibody bevacizumab were
promising, the efficacy in the clinic was limited, leading to
withdrawal of the FDA (Food and Drug Administration) approval
as adjuvant therapy for breast cancer.5 In addition to antibodies,
kinase inhibitors like SU5416 (Semaxanib), a selective VEGF
receptor tyrosine kinase inhibitor, have been developed. SU5416
was used as an adjuvant treatment in patients with advanced
colorectal cancer, but the phase-III trial was halted because of a
lack of clinical benefit (NCT00021281). A phase-I clinical trial for
SU5416 in inflammatory breast cancer has been completed in
2010, but no results have been reported thus far (NCT00005822).
The limited clinical benefit of antiangiogenic therapies is most
likely caused by therapy resistance,6 characterized by an initial
response to treatment followed by patient relapse. This can be
caused by upregulation of alternative proangiogenic signaling
pathways,7 for example, the endoglin/transforming growth factor-
β (TGF-β) pathway.
Endoglin is a co-receptor for TGF-β and bone morphogenetic
protein-9 (BMP-9) and is highly expressed on angiogenic
endothelial cells.8–10 Endoglin is indispensable for developmental
angiogenesis as has been shown by embryonic lethality of
endoglin knockout mice.11–13 In cancer, previous studies have
shown a clear correlation between endoglin microvessel density
and patient survival.14–17 BMP-9 and TGF-β can, upon binding to
endoglin, induce phosphorylation of downstream Smad proteins,
inducing an angiogenic phenotype.18 TRC105 is a chimeric IgG1
monoclonal antibody that binds human endoglin with high
affinity and is currently being tested in clinical trials as
antiangiogenic therapy.19 TRC105 prevents BMP-9 binding to
endoglin and induces an antibody-dependent cytotoxicity
response leading to apoptosis of endoglin-expressing cells.20
Results of a phase-I clinical trial showed safety of the antibody in
patients with various solid cancers, and in two patients even
clinical benefit was observed for a prolonged period of time.19
Recently, a phase-IB clinical trial was completed showing that the
combination of TRC105 and bevacizumab was safe and even
resulted in reduced tumor volumes in some bevacizumab-
resistant patients.21
In the present study, we have assessed the inhibition of
angiogenesis by simultaneous targeting of the endoglin and VEGF
pathway. In vitro and in vivo angiogenesis models and an
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orthotopic breast cancer mouse model show increased inhibition
of angiogenesis by combining TRC105 and SU5416. Even more
striking, endoglin targeting, using a neutralizing antibody or
ligand trap, strongly inhibits the metastatic spread of breast
cancer cells.
RESULTS
Anti-VEGF treatment in patients increases endothelial Smad1
phosphorylation
First, the potential redundancy between the endoglin and VEGF
pathway in angiogenesis was examined. We had access to a small
cohort of rectal cancer patients treated in a neoadjuvant setting
with anti-VEGF therapy (bevacizumab), providing us with pre-
treatment biopsies and post-treatment resection specimens.
Tissue sections from patients treated with bevacizumab were
stained for phosphorylated Smad1 (pSmad1), the major signaling
molecule downstream of endoglin. Pretreatment biopsies
(Figure 1a, upper panel) showed limited staining for pSmad1 in
the endothelial nuclei compared with the resection specimen
from the same patient after bevacizumab, where almost all
endothelial nuclei showed strong pSmad1 accumulation
(Figure 1a, lower panel). To exclude that this observation was



























































Figure 1. Anti-VEGF treatment results in increased Smad1 phosphorylation. (a) Immunohistochemical staining for pSmad1 revealed increased
endothelial nuclear pSmad1 in tissue samples from patients treated with bevacizumab (lower panel) compared with pretreatment tumor
biopsies (upper panel). (b) Treatment with bevacizumab in combination with chemoradiation therapy (lower panel) increased pSmad1 in
endothelial nuclei compared with chemoradiation treatment only (upper panel). White arrowheads indicate pSmad1-negative nuclei, and
black arrowheads indicate pSmad1-positive nuclei. Magnification × 200, right panels × 400.
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group of patients who only received chemoradiation therapy
(standard of care, Figure 1b, upper panel) was compared with a
group receiving both chemoradiation therapy and bevacizumab
(Figure 1b, lower panel). These data confirmed increased nuclear
accumulation of pSmad1 in endothelial cells upon anti-VEGF
therapy. These results indicate that, upon VEGF inhibition,
alternative pathways like the endoglin pathway seem to be
upregulated in cancer patients.
Endoglin and VEGF pathways are connected in vitro
Next, we examined whether redundancy could also be observed
between endoglin and VEGF pathways in vitro. Human umbilical
vein endothelial cells (HUVECs) were stimulated with VEGF or
BMP-9, the main endoglin ligand. Treatment with BMP-9 induced
rapid Smad1 phosphorylation that could transiently be inhibited
by TRC105 (Figure 2a). In addition to inhibiting Smad1 phosphor-
ylation, TRC105 increased phosphorylation of the anti-angiogenic
Smad2 (Figure 2b, left panel and Supplementary Figure S1A)
similar to stimulation with 5 ng/ml TGF-β (Figure 2b, right panel).
Smad2 phosphorylation was dependent on ALK-5 (activin
receptor-like kinase-5) kinase activity, as treatment with the kinase
inhibitor SB431542 abrogated TRC105-induced Smad2 phosphor-
ylation (Figure 2b, right panel). These data indicate a shift toward
an antiangiogenic response by TRC105. VEGF induced rapid
extracellular signal-regulated kinase (ERK) phosphorylation in
HUVECs that could be inhibited by SU5416 (Figure 2c). Interest-
ingly, when HUVECs were treated with TRC105 and subsequently
stimulated with VEGF, we observed increased ERK phosphoryla-
tion as compared with VEGF stimulation without TRC105
pretreatment (Figure 2d and Supplementary Figure S1B). This
did not seem to be due to increased VEGFR2 Tyr1175
phosphorylation (Supplementary Figure S1C). These results
suggest a connection between the endoglin and VEGF signaling
pathways in endothelial cells.
Combined endoglin and VEGF targeting inhibits angiogenesis
If there is redundancy between the endoglin and VEGF pathways,
simultaneous inhibition of both pathways could result in increased
and sustained antiangiogenic responses. Therefore, we assessed
the effects of TRC105, SU5416 and combination treatment on
in vitro proliferation, migration and angiogenesis. TRC105 did not
significantly affect HUVEC proliferation, whereas both SU5416 and
the combination treatment resulted in statistically significant
inhibition of HUVEC proliferation (Figure 3a). Under serum-free
conditions (Figure 3b), or serum-free medium supplemented with
either VEGF or BMP-9 (Supplementary Figure S2), we observed the
same inhibitory effects on proliferation of HUVECs by SU5416 and
combination treatment, although more pronounced. In contrast to
BMP-9, VEGF enhanced HUVEC proliferation (Figure 3c), under-
lining the importance of VEGF for endothelial cell proliferation
in vitro.
As next to proliferation, migration of endothelial cells plays an
additional role in angiogenesis, the cord-forming ability of
HUVECs in the presence of the inhibitors was assessed. First,
we optimized the percentage of fetal calf serum in the medium
for this assay, shown to be 5% (Supplementary Figure S3A).
TRC105 did not significantly inhibit the number of closed
polygons (Figure 3d), or the number of branches per branchpoint
(Supplementary Figure S3B), whereas SU5416 strongly inhibited
both read-outs of the angiogenic potential. Without further
decreasing the number of closed polygons, additional effects of
TRC105/SU5416 treatment on the cord morphology and integrity
of the remaining cords were observed. The cell aggregates that
were formed were less dense and appeared to disintegrate faster
than in the other conditions. Next, angiogenic potential in a
more complex three-dimensional spheroid model for angiogen-
esis was assessed. HUVEC spheroids were embedded in the
presence of the inhibitors, stimulated and average sprout length
was determined (Supplementary Figure S3C). TRC105 did not
affect endothelial sprouting (Figure 3e), confirming the results of
the cord formation assay. A trend towards decreased average
sprout length was observed for SU5416, whereas combination
treatment resulted in statistically significant decreased HUVEC
sprouting (Figure 3e). These data indicate that endothelial









































































































































Figure 2. Redundancy between endoglin and VEGF signaling in HUVECs in vitro. (a) BMP-9 stimulation (10 min) induced strong pSmad1 in
HUVECs, inhibited by TRC105. (b) Overnight treatment with TRC105 increased pSmad2 (left panel) to a comparable level as induced by TGF-β
(1 h). This effect was completely blocked by the ALK-5 kinase inhibitor SB431542 (right panel). (c) VEGF stimulation (10 min) increased ERK1/2
phosphorylation (pERK) that can be inhibited by SU5416. (d) Pretreatment with TRC105 increased VEGF-induced pERK that can be reverted by
SU5416 or TRC105/SU5416 combination therapy. All western blots are representative of three independent experiments.
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Figure 3. TRC105/SU5416 combination therapy enhances antiangiogenic effects. TRC105 does not inhibit HUVEC proliferation in an MTS
proliferation assay, whereas SU5416 and TRC105/SU5416 combination significantly decreased proliferation in both full serum (a) and serum-
free conditions (b). VEGF, either supplemented or BPE derived, stimulated HUVEC proliferation, whereas BMP-9 did not show an effect (c). Data
represent mean of two independent experiments performed in triplicate. (d) HUVEC endothelial cells were seeded on matrigel and allowed to
form endothelial cords. Endothelial cord-forming capacity of HUVECs was assessed after overnight incubation with the inhibitors. TRC105 did
not affect cord formation, whereas SU5416 treatment decreased the number of closed polygons. TRC105/SU5416 combination enhanced
these effects on cord morphology, but not on the number of closed polygons. Data are normalized to control and represent mean of three
independent experiments performed in triplicate. (e) In three-dimensional HUVEC sprouting assays, sprouting of HUVECs was not affected by
TRC105, whereas SU5416 and especially the TRC105/SU5416 combination significantly reduced sprouting. Data represent mean of three
independent experiments performed in triplicate. *P⩽ 0.05, **P⩽ 0.01.
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TRC105/SU5416 combination enhances angiogenesis inhibition in
zebrafish
To further study the effect of inhibiting VEGF and endoglin in a
multicellular model for angiogenesis, we used Fli:eGFP zebrafish,
in which all blood vessels express green fluorescent protein (GFP).
First, we analyzed whether TRC105, raised against human
endoglin, was able to bind zebrafish endoglin. Human IgG
(negative control) and TRC105 were fluorescently labeled and
injected into zebrafish embryos. At 2 days after injection, TRC105
(red) colocalized with the GFP-expressing zebrafish endothelium,
whereas no red fluorescent signal was observed in the IgG control
(Figure 4a), implying that TRC105 binds to the zebrafish
endothelium. Next, we determined the antiangiogenic effects of
combination treatment. Zebrafish embryos were injected with
TRC105, whereas SU5416 was applied via the fish water. At 2 days
after treatment, the phenotype of the subintestinal vessels was
scored as either normal or mildly or severely affected (Figure 4b).
Both TRC105 and SU5416 monotherapy increased the frequency
of mainly the severe phenotype (from 4.4 to 9.1% (TRC105) and
9.0% (SU5416), Figure 4b), whereas normal vessel development
was decreased further after treatment with the TRC105/SU5416
combination (from 81.6 to 61.2%, Figure 4b). These data show
increased inhibition of angiogenesis in zebrafish embryos with
combined endoglin and VEGF targeting.
Combined targeting of the endoglin and VEGF pathway inhibits
tumor angiogenesis in vivo
Next, we evaluated the effects of TRC105/SU5416 combination












































Figure 4. TRC105/SU5416 treatment inhibits angiogenesis in zebrafish. (a) The 2-day-old zebrafish embryos were injected with red
fluorescently labeled human IgG or TRC105. TRC105 showed binding to GFP-expressing zebrafish vasculature (right panel), whereas the IgG
control did not show any fluorescent signal (left panel). (b) Development of the subintestinal vessels (SIVs) was assessed after 2 days of
treatment with either TRC105, SU5416 or the combination. The SIVs were scored as normal phenotype or mildly or severely affected. TRC105
and SU5416 both increased the affected phenotypes, whereas TRC105/SU5416 combination enhanced this effect even more. Data represent
mean percentage of fish with the observed phenotype from three independent experiments (n = 38–114 fish/group/experiment).
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Luciferase-expressing KEP1-11 mouse breast cancer cells22 were
transplanted into the mouse mammary gland. Tumor growth and
metastasis were followed by in vivo bioluminescent imaging. The
data showed that neither treatment with TRC105 or SU5416 nor
combination treatment affected tumor volume assessed by

































































































































































































































































































Figure 5. Combined targeting of endoglin and VEGF decreases tumor vascular density and metastatic spread of mouse breast cancer. KEP1-11
breast cancer cells were orthotopically transplanted and tumor growth was followed for 6 weeks using bioluminescent imaging (a) and caliper
measurements (b). At the end of the experiment (6 weeks) tumor volume was not affected by the treatment, whereas tumor vascular density
(CD31 (c) and endoglin (d) immunohistochemical staining) was strongly reduced upon TRC105 or SU5416 treatment, and even further
decreased by TRC105/SU5416 combination. (e) Smooth muscle actin-positive (SMA+) stroma content of tumors was significantly reduced
upon treatment with TRC105, either as monotherapy or in combination with SU5416 (n= 4–6 mice/group, average number of positive pixels).
(f) Mice treated with TRC105, either as monotherapy or in combination with SU5416, show a decreased number of metastases (6 weeks after
start of experiment, n= 4–6 mice/group). *P⩽ 0.05, **P⩽ 0.01.
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Treatment with TRC105 or TRC105/SU5416 combination increased
VEGF expression in tumor homogenates (Supplementary Figure
S4A), whereas VEGF plasma levels were only increased upon
TRC105 treatment (Supplementary Figure S4B). Using quantitative
PCR, enhanced endoglin expression was observed after SU5416
and combination treatment (Supplementary Figure S4C). Next,
tumor vascularization was assessed by CD31 and endoglin
staining. Vascular density was decreased by both TRC105 and
SU5416, but the effects were significantly enhanced upon
combination treatment (Figures 5c and d). Interestingly, the
inhibitory effects of TRC105 on microvessel density determined by
endoglin were stronger than determined by CD31, indicating
specific targeting of endoglin-expressing vessels. Staining for
smooth muscle actin-positive cancer-associated fibroblasts (CAFs)
revealed strongly reduced numbers of CAFs only in the TRC105
and combination treatment groups (Figure 5e). Furthermore, a
dramatic reduction in metastases was observed upon TRC105
monotherapy or in combination with SU5416 (Figure 5f). SU5416
monotherapy did not reduce metastatic spread. Taken together,
these data show enhanced inhibition of tumor angiogenesis by a
combination of TRC105 and SU5416. Importantly, TRC105 seems
to have a strong inhibitory effect on metastatic spread.
TRC105 inhibits breast cancer metastasis
In order to more specifically assess the effects of TRC105
on tumor metastasis, we used a clinically relevant mouse model
of breast cancer metastasis. At 4 weeks after transplantation, the
primary tumor was removed and mice received adjuvant
treatment with TRC105 or human IgG (Figure 6a). At the time
of resection, average tumor volumes were equal in both groups
(data not shown). Complete resection of the primary tumor was
confirmed by bioluminescent imaging. At 6 weeks after
resection, bioluminescent imaging showed a high number of
metastases in the IgG control group, and this was strongly
reduced in the TRC105-treated group (Figure 6b). The percen-
tage of mice bearing metastases in the TRC105 treatment group
(28.3%) was strongly decreased when compared with the IgG
control group (75%, Figure 6c). Microvessel density in the
metastases did not differ between the treatment groups,
although only a low number of metastases could be evaluated
(data not shown). In addition, morphology of the primary
tumor and metastases was similar in both treatment groups
(Supplementary Figure S5). Bioluminescent signals in the
TRC105-treated mice were derived from small lesions not
invading the underlying tissue at the location of the primary
tumor, whereas metastases in the IgG treatment group were
found mainly in draining lymph nodes, bone and peritoneal wall.
Only 4 out of 12 mice treated with TRC105 showed distant
metastases, resulting in significantly improved metastasis-free
survival of this group (Figure 6d). These data indicate that
adjuvant treatment with TRC105 prevents the development of
distant breast cancer metastases.

































































































































Figure 6. TRC105 treatment inhibits breast cancer metastasis in adjuvant setting. (a) Experimental set-up. At 4 weeks after tumor
transplantation, primary tumors were resected and mice were treated with human IgG or TRC105 for 6 additional weeks. (b) Metastasis
formation was followed over time using bioluminescence. Mice treated with TRC105 showed significantly less metastatic lesions when
compared with the IgG control group (n= 11–12 mice/group), decreasing the percentage of mice with metastases to 28.3% as compared with
75% in the control mice (c). This results in significantly improved metastasis-free survival of mice treated with TRC105 compared with IgG
treatment group (d). Graphs represent mean of 11–12 mice/group from two independent experiments. *P⩽ 0.05.
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Endoglin targeting using endoglin-Fc decreases metastatic spread
To confirm that inhibition of metastasis is indeed caused by
targeting endoglin, an alternative approach was used, using an
endoglin ligand trap. KEP1-11 cell lines stably expressing either
endoglin-Fc or control Fc (Supplementary Figure S6A) were
orthotopically transplanted and tumor growth was monitored
using bioluminescence and caliper measurements. Comparable to
TRC105, endoglin-Fc expression did not affect tumor volume
(Supplementary Figures S6B and C), whereas endoglin-Fc strongly
decreased primary tumor vascularization (Supplementary Figure
S6D). Interestingly, like treatment with TRC105, mice with
endoglin-Fc-expressing tumors exhibited a reduced number of
metastases (Supplementary Figure S6E).
To assess the effects of endoglin-Fc after primary tumor
resection, tumor cells expressing Fc or endoglin-Fc were
orthotopically transplanted and allowed to grow for 4 weeks.
Primary tumors were removed and mice were monitored for an
additional 6 weeks (Figure 7a). Upon resection, the number of
smooth muscle actin-positive CAFs in the primary tumors was
significantly lower in the endoglin-Fc group compared with the Fc
control group (Figure 7b). At the end of the experiment,
bioluminescent signals in the endoglin-Fc group were significantly
reduced as compared with the Fc group (Figure 7c). Expression of
endoglin-Fc resulted in decreased metastatic spread and therefore
improved metastasis-free survival (Figure 7d). In addition, the
percentage of mice showing distant metastases decreased by
450% in the mice bearing endoglin-Fc-expressing tumors
(Figure 7e). Taken together, our results show that targeting
endoglin, by TRC105 or endoglin-Fc, strongly decreases the
metastatic spread of mouse breast cancer cells in vivo and opens
possibilities to explore adjuvant TRC105 treatment in breast
cancer patients.
DISCUSSION
In this study we show that targeting endoglin, using an antibody
or ligand trap, decreases metastatic spread of breast cancer
in vivo. Combined targeting of the endoglin and VEGF pathway
results in decreased angiogenic capacity of human endothelial
cells in vitro, in a zebrafish model for angiogenesis and in a mouse
model for invasive breast cancer.
In vitro, TRC105 did not inhibit the angiogenic capacity of
HUVECs. Contrary to our observations, Liu et al.23 described a




































































































































































Figure 7. Endoglin-Fc expression decreases metastatic spread of breast cancer cells. (a) Experimental set-up. At 4 weeks after tumor
transplantation of cell lines stably expressing Fc or Endoglin-Fc, tumors were resected and metastatic spread was followed for 6 additional
weeks. (b) Smooth muscle actin-positive (SMA+) stroma content of the primary tumors was strongly decreased by tumoral endoglin-Fc
expression when compared with the Fc group. (c) Bioluminescent imaging showed significant reduction of metastatic spread in the endoglin-
Fc group when compared with Fc-expressing tumors (n= 8 mice/group). (d) Expression of endoglin-Fc by the tumor results in improved
metastasis-free survival. (e) The percentage of mice showing distant metastases was decreased in the endoglin-Fc group by 450% compared
with Fc. Graphs represent mean of eight mice/group from two independent experiments. **P⩽ 0.01, ***P⩽ 0.001.
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significant decrease of HUVEC tube formation, migration and
proliferation upon treatment with 100 μg/ml TRC105, a much
higher dose than used in this study. In the same study, additional
effects of TRC105 treatment combined with the anti-VEGF agent
bevacizumab were reported, supporting our data on redundancy
between the endoglin and VEGF signaling pathways.24 The limited
effects of TRC105 observed in vitro can be explained by the
working mechanism of TRC105. Additional to preventing BMP-9
binding to endoglin,20 TRC105 induces antibody-dependent cell-
mediated cytotoxicity, requiring immune cells. Therefore, the
presence of an intact immune system increases TRC105 efficacy25
and might lead to enhanced effects.
Although xenograft studies showed very promising results for
antiangiogenic therapy and initial responses were observed,
patients relapse and actual clinical benefits are limited. In this
study we show increased endothelial phosphorylated Smad1
(indicating endoglin signaling) in tumor tissues of cancer patients
treated with bevacizumab. In a study on circulating protein
biomarkers in TRC105-treated patients, the authors reported that
certain angiogenic biomarkers, like VEGF, were significantly
downregulated shortly after starting TRC105 treatment, indicating
inhibition of multiple angiogenic pathways.26 However, at the end
of the study, the same proangiogenic factors were upregulated,
implying a switch to alternative angiogenic pathways. Therefore,
combined targeting of the endoglin and VEGF pathway could
result in enhanced and sustained inhibition of angiogenesis.
Indeed, in our breast cancer model, tumor angiogenesis was
more strongly inhibited by TRC105/SU5416 combination
therapy that unfortunately did not result in decreased tumor
volumes. Treatment with bevacizumab can result in vessel
normalization.27,28 Leaky and irregular tumor vessels partly
disappear, but the remaining vessels gain ‘normal’ morphology
and pericyte coverage.29 This results in increased blood and
nutrient supply to the tumor, sustaining tumor growth, and also
enhanced effects of chemotherapy on breast cancer as we could
recently show for antiangiogenic therapy targeting ALK-1.30
Recently, the first clinical trial assessing TRC105 and bevaci-
zumab combination in patients has been published.21 Of the 38
patients enrolled in this trail, 18 patients showed at least a partial
response to treatment. In all, 14 patients had decreased overall
tumor burden, of which 10 patients progressed earlier while
receiving anti-VEGF treatment, but still responded to TRC105
therapy, suggesting that combination therapy could circumvent
therapy resistance. Side effects of combined targeting were
limited and not observed more often than with single drug
treatment,21 opening doors for clinical use. In addition, a phase-I
clinical trial in prostate cancer patients showed almost no classic
antiangiogenesis adverse effects upon TRC105 monotherapy.31
The safety and clinical efficacy of combined TRC105 and anti-VEGF
treatment is now being explored in patients with recurrent
glioblastoma multiforme (NCT01648348), advanced renal cell
cancer (NCT01727089) and other solid tumors (NCT01975519,
NCT01306058, NCT01806064).
One of the key findings in this study was the strong inhibition of
breast cancer metastasis by endoglin targeting, either by TRC105
or the ligand trap endoglin-Fc. In contrast to our observations,
Anderberg et al.32 reported that endoglin heterozygous mice
show increased liver metastasis in Rip-Tag mice. Endoglin
heterozygote mice develop a hereditary hemorrhagic telangiecta-
sia phenotype including vascular malformations33 and increased
vascular permeability,34 possibly resulting in enhanced metastatic
spread. When we treated endothelial monolayers with TRC105,
transendothelial migration of KEP1-11 cells did not change
compared with human IgG treatment (data not shown), suggest-
ing that TRC105 does not directly affect endothelial permeability
in vitro. Another study also showed decreased metastatic
spread of prostate cancer in endoglin heterozygous mice.35
These observations imply that both tumor type and method of
endoglin targeting could determine metastatic capacity of the
cancer cells.
How endoglin mechanistically contributes to metastasis forma-
tion is subject of ongoing studies. As we used a model in which
endoglin-Fc is expressed by the tumor cells and therefore present
before the angiogenic switch, it is unlikely that decreased
metastasis formation is solely due to inhibition of the angiogenic
switch. Tumor vessel normalization could prevent tumor cell
intravasation and thereby spreading throughout the body. KEP1-
11 cells, in contrast to some other breast cancer cells in vitro,36
hardly express endoglin or VEGFR2 (Supplementary Figure S7),
and therefore direct targeting of the tumor cells in our model is
unlikely. However, besides endothelial cells, endoglin is also
expressed in other cells in the tumor microenvironment. For
example, TRC105 can reduce the number of regulatory T cells in
prostate tumors, implying a shift from the presence of regulatory
T cells to cytotoxic T cells.31 In addition, macrophages can express
endoglin,37 in which it can direct macrophages in either a tumor-
suppressive M1 or tumor-promoting M2 phenotype.38
Our study revealed that treatment with TRC105 or expression of
endoglin-Fc resulted in decreased smooth muscle actin-positive
CAF content of the tumors (Figures 5e and 7b). The percentage of
tumor stroma is known to be a prognostic marker in breast
cancer.39,40 More specifically, CAFs have been shown to play an
important role in breast cancer progression and metastasis
(reviewed in Khamis et al.41). We and others35 have shown that
endoglin is expressed by CAFs in diverse types of cancer.
A possible explanation for the observed effects could be that
treatment with TRC105 or endoglin-Fc might decrease these
endoglin-expressing CAFs that stimulate tumor growth and
metastasis.
In a phase-I clinical trial, preliminary evidence of clinical activity
on pre-existing metastases upon treatment with TRC105 was
observed.19 A castrate-resistant prostate cancer patient showed
markedly improved metastatic bone lesions upon TRC105
treatment. In another patient, with chemotherapy-resistant uterus
carcinoma, a strong decrease in pulmonary metastases was
observed after TRC105 treatment. These results, combined with
our study showing that even in an adjuvant setting TRC105 could
decrease metastatic dissemination, suggest a role for endoglin in
initiating and sustaining distant metastases.
In conclusion, we have shown that dual targeting of the endoglin
and VEGF pathway increases antiangiogenic responses in vitro and
in vivo as compared with monotherapy. Most importantly, we show
that targeting of endoglin, either using a neutralizing antibody or a
ligand trap, inhibits the metastatic spread of breast cancer in vivo. In
the light of ongoing trials, our data suggest a potential important
role for targeting endoglin in breast cancer metastasis.
MATERIALS AND METHODS
Patient samples
Paraffin-embedded tissue samples were obtained from the Department of
Surgery, Leiden University Medical Center. The patient population
contained stage I–IV rectal cancer patients treated in a neoadjuvant
setting with bevacizumab. Samples were presurgery tumor biopsies (N= 5)
and tumor tissue obtained after surgery (N= 3). In addition, tumor tissue
samples from patients treated with only chemoradiation therapy (N= 8) or
a combination of chemoradiation and bevacizumab (N= 11) were
evaluated. Patient characteristics and follow-up were recorded by the
Department of Surgery. Samples were used according to the guidelines of
the Medical Ethics Committee of the Leiden University Medical Center.
Tissue analysis
Immunohistochemical stainings were performed as described before42
using antibodies against CD31 (sc-1506-R Santa Cruz Biotechnologies,
Santa Cruz, CA, USA), endoglin (BAF1097 R&D Systems, Abington, UK) or
phosphorylated Smad1 (9511 Cell Signaling Technologies, Danvers, MA,
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USA). Four representative fields per tumor slide were photographed with a
Leitz Diaplan microscope (Leitz, Wetzlar, Germany) and staining was
quantified using ImageJ software (National Institutes of Health, Bethesda,
MD, USA; http://imagej.nih.gov/ij/). Enzyme-linked immunosorbent assay
analysis for mouse VEGF was performed according to the manufacturer’s
instructions (DY493, R&D Systems). BMP-9 enzyme-linked immunosorbent
assay and quantitative PCR analyses were performed as described
before.43,44 Primers are described in Supplementary Table S1.
Cell culture and signaling assays
Primary HUVECs were cultured as described before.45 P53/E-cadherin
double-knockout mouse breast cancer cells (KEP1-11)22 were cultured as
described before30 and monthly tested for mycoplasma contamination.
3 × 105 HUVEC cells were seeded in gelatin-coated six-well plates. Upon
90% confluency, cells were serum starved overnight in medium containing
either 40 μg/ml TRC105 (Tracon Pharmaceuticals, San Diego, CA, USA) or
40 μg/ml human IgG (BioXCell, West Lebanon, NH, USA). At 30 min before
stimulation, 0.1% dimethyl sulfoxide (DMSO, as solvent control) or 1 μM
SU5416 (WuXi AppTec, Shanghai, China) was added, followed by a 10-min
stimulation with either 0.1 ng/ml recombinant human BMP-9 (R&D
Systems), 5 ng/ml TGF-β3,46 or 50 ng/ml recombinant human VEGF
(Peprotech, London, UK). For TGF-β signaling studies, HUVECs were
starved overnight in the presence of TRC105, IgG, the ALK-5 inhibitor
SB431542 (Tocris, Bristol, UK) or combinations. Next day, cells were
stimulated with 5 ng/ml TGF-β3. Cells were lysed in RIPA buffer (150 mM
NaCl, 1% NP-40, 0.25% deoxycholate, 0.1% SDS, 50 mM Tris (pH 8.0), 2 mM
EDTA, 1 mM NaVO4, 10 mM NaF and 1 mM sodium orthovandate (BDH
Laboratory, Poole Dorstet, UK)), protein content was determined and
western blot analysis was performed as described before.44 Membranes
were incubated overnight with primary antibodies against endoglin
(R&D Systems), phosphorylated Smad1, phosphorylated Smad2, phos-
phorylated VEGFR2 Tyr1175 (9511, 3108, 2478, all from Cell Signaling
Technologies) or phosphorylated ERK1/2 (SAB4301578, Sigma-Aldrich,
Zwijndrecht, The Netherlands). Blots were stripped and reprobed with
either mouse anti-GAPDH (AB2302 Millipore, Amsterdam, The Netherlands)
or mouse anti-β-actin (A2228, Sigma-Aldrich) antibodies as loading
controls. Densitometry analysis was performed using ImageJ software
(National Institutes of Health).
MTS proliferation assay
HUVECs (2500 cells per well) were seeded in 96-well plates in triplicate.
After 16 h, medium was replaced with 100 μl medium supplemented with
40 μg/ml TRC105, 1 μM SU5416 or controls. In addition, the assay was also
performed in serum-free medium, containing bovine pituitary extract, and
in the presence of 50 ng/ml recombinant human VEGF or 0.1 ng/ml BMP-9.
At indicated time points, 20 μl MTS substrate (Promega, Madison, WI, USA)
was added to each well and absorbance was measured at 490 nm (Perkin
Elmer, Groningen, The Netherlands).
In vitro angiogenesis assays
HUVECs were resuspended in M199 medium, supplemented with 5% fetal
calf serum and 0.2% heparin. 2 × 104 HUVECs were seeded in matrigel
(BD Biosciences, Breda, The Netherlands)-coated 96-well plates in the
presence of 40 μg/ml TRC105, 1 μM SU5416 or controls. After 16 h of
incubation, five images per well were acquired at 40× magnification. The
number of branches per branchpoint and the number of closed polygons
were analyzed in a blinded manner by two independent observers.
The endothelial sprouting assay was performed as described before.47
In short, HUVEC spheroids were embedded in collagen-I containing 0 or 20%
fetal calf serum, and supplemented with 40 μg/ml TRC105, 1 μM SU5416 or
controls. Images were acquired after overnight incubation and average sprout
length was calculated using ImageJ software (National Institutes of Health).
Zebrafish
TRC105 and human IgG were labeled with Dyelight 594 NHS-Ester
fluorescent dye (Life Technologies Europe, Bleiswijk, The Netherlands) and
1 ng antibody was injected in the blood island of 2–day-old Fli:eGFP
zebrafish embryos. At 2 days after injection, embryos were fixed and green
and red fluorescent signals were analyzed. For angiogenesis assays, Fli:
eGFP transgenic zebrafish were injected in the blood island 28 h post
fertilization with either 1 ng human IgG or TRC105. SU5416 (0.5 mg/ml) or
DMSO was supplied in the fish water. Zebrafish embryos were analyzed
3 days post fertilization using confocal microscopy (Leica TCS-SP5 STED,
Leica, Rijswijk, The Netherlands).
Mouse breast cancer model
All animal experiments were approved by the Dutch animal ethics
committee. The 9-week-old female Balb/c nu/nu mice (Charles River,
L’Arbresle Cedex, France) were anesthetized and 3× 105 luciferase-
expressing KEP1-11 cells were injected in the fourth mammary gland as
described before.30 Mice were intraperitoneally injected with 100 mg/kg
luciferin, and imaged on the IVIS Lumina-II (Caliper Life Sciences,
Hopkinton, MA, USA). Animals were treated twice weekly starting at week
2 after transplantation with 0.9% NaCl (n= 4), 15 mg/kg human IgG and
DMSO, 50 mg/kg SU5416 and 15 mg/kg human IgG, 15 mg/kg TRC105 and
DMSO or 15 mg/kg TRC105 and 50 mg/kg SU5416 (all n= 6) intraper-
itoneally. Time between treatment with DMSO or SU5416 and human IgG
or TRC105 was at least 24 h. Tumor volume was measured twice weekly
using a caliper and calculated (tumor volume= (width2 × length)/2). After
6 weeks, mice were killed and blood and tissue samples were collected.
For the tumor resection model, tumors were transplanted as described
above and allowed to grow for 4 weeks. Mice were anesthetized with KSA
and the primary tumor was resected.48 Complete removal of the tumor
was confirmed by bioluminescent imaging. Twice-weekly adjuvant
treatments with either 15 mg/kg human IgG (n= 11) or TRC105 (n= 12)
were started 1 week after tumor resection (Figure 6a). Mice were imaged
weekly for an additional 6 weeks to determine metastatic spread.
Orthotopic breast cancer using stable cell lines
Fc and Endoglin-Fc (a fusion protein consisting of the endoglin extracellular
domain and Fc region of an antibody)-expressing plasmids were cloned into
lentiviral expression vectors. Stable cell lines were generated by puromycin
selection (5 μg/ml, Sigma-Aldrich). Expression of the constructs was
confirmed using western blot. Transplantation, resection and imaging of
the tumors were performed as described above. Mice (n=8/group) were
killed after 7 weeks (primary tumor) or 10 weeks (resection).
Statistical analysis
For in vivo experiments power calculations were performed to determine
appropriate group sizes. Mice were divided in groups with equal tumor
volumes and not randomized. Treatment was not blinded, whereas
analysis of tissues was performed in a blinded manner with two
independent observers. Data indicate mean± s.e.m. as indicated in figure
legends. Differences between two groups were calculated using Student’s
t-test or Mann–Whitney test. Survival curves were generated using Kaplan–
Meier analysis and the log-rank test. P-values of o0.05 were considered
significant.
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